You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for New Drug Application (NDA): 021116


✉ Email this page to a colleague

« Back to Dashboard


NDA 021116 describes THYRO-TABS, which is a drug marketed by Alvogen and is included in one NDA. It is available from eleven suppliers. Additional details are available on the THYRO-TABS profile page.

The generic ingredient in THYRO-TABS is levothyroxine sodium. There are ten drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
Summary for 021116
Tradename:THYRO-TABS
Applicant:Alvogen
Ingredient:levothyroxine sodium
Patents:0
Pharmacology for NDA: 021116
Suppliers and Packaging for NDA: 021116
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
THYRO-TABS levothyroxine sodium TABLET;ORAL 021116 NDA Alvogen, Inc. 47781-640 47781-640-10 1000 TABLET in 1 BOTTLE (47781-640-10)
THYRO-TABS levothyroxine sodium TABLET;ORAL 021116 NDA Alvogen, Inc. 47781-640 47781-640-90 90 TABLET in 1 BOTTLE (47781-640-90)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date:Oct 24, 2002TE:AB1,AB2,AB3,AB4RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date:Oct 24, 2002TE:AB1,AB2,AB3,AB4RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date:Oct 24, 2002TE:AB1,AB2,AB3,AB4RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.